Literature DB >> 31760506

Balanitis xerotica obliterans: an update for clinicians.

Alexander T M Nguyen1, Andrew J A Holland2.   

Abstract

Lichen sclerosus (LS) is a severe, chronic, dermatosis characterised by inflammatory, sclerotic, pruritic lesions that causes significant morbidity in patients of all genders and ages. In boys, the lesions typically affect the foreskin and glans (termed balanitis xerotica obliterans (BXO)), leading to phimosis and potentially meatal stenosis. The incidence of the disease is not well reported but the average age of affected boys is 8 years (range 1-16). Diagnosis can often be made clinically, although histological study remains important to rule out important differential diagnoses. Complications include genital scarring, urinary and sexual dysfunction as well as the development of carcinomas in adult life. Circumcision has been regarded as definitive management of BXO in boys, but this may be supplemented with medical therapies such as topical steroids, immune modulators, intralesional triamcinolone and ozonated olive oil. Supportive measures including emollients, avoidance of irritants, surveillance of complications and recurrence as well as education and counselling remain important.
Conclusion: BXO remains an important cause of phimosis in boys. The frequency of this condition appears unclear but seems likely to be less than 1% of males. Treatment generally involves circumcision, with some evidence that topical steroids or immunomodulators may decrease the incidence of recurrent meatal stenosis.What is Known:• Surgical circumcision is considered the definitive management of BXO• Many aspects of BXO are still in contention or require further study including the epidemiology and aetiology.What is New:• There is increasing awareness of non-surgical modalities that may be used in adjunct to surgery including topical corticosteroids, immune modulators, intralesional triamcinolone and ozonated olive oil• Awareness of meatal stenosis-related BXO has led to the development of surgical techniques such as preputioplasty as well as buccal mucosal inlay grafts.

Entities:  

Keywords:  Balanitis xerotica obliterans; Circumcision; Lichen sclerosus; Meatal stenosis

Mesh:

Substances:

Year:  2019        PMID: 31760506     DOI: 10.1007/s00431-019-03516-3

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  56 in total

Review 1.  The treatment of balanitis xerotica obliterans.

Authors:  I Depasquale; A J Park; A Bracka
Journal:  BJU Int       Date:  2000-09       Impact factor: 5.588

Review 2.  Balanitis xerotica obliterans: a review of diagnosis and management.

Authors:  Olivia A Charlton; Saxon D Smith
Journal:  Int J Dermatol       Date:  2018-10-12       Impact factor: 2.736

3.  Management of boys with abnormal appearance of meatus at circumcision for balanitis xerotica obliterans.

Authors:  C Holbrook; T Tsang
Journal:  Ann R Coll Surg Engl       Date:  2011-09       Impact factor: 1.891

4.  The incidence of phimosis in boys.

Authors:  K R Shankar; A M Rickwood
Journal:  BJU Int       Date:  1999-07       Impact factor: 5.588

5.  The response of balanitis xerotica obliterans to local steroid application compared with placebo in children.

Authors:  A Kiss; A Csontai; L Pirót; P Nyirády; M Merksz; L Király
Journal:  J Urol       Date:  2001-01       Impact factor: 7.450

6.  Does application of topical steroids for lichen sclerosus (balanitis xerotica obliterans) affect the rate of circumcision? A systematic review.

Authors:  Semiu E Folaranmi; Harriet J Corbett; Paul D Losty
Journal:  J Pediatr Surg       Date:  2018-01-03       Impact factor: 2.545

7.  High incidence of balanitis xerotica obliterans in boys with phimosis: prospective 10-year study.

Authors:  András Kiss; László Király; Balázs Kutasy; Miklós Merksz
Journal:  Pediatr Dermatol       Date:  2005 Jul-Aug       Impact factor: 1.588

Review 8.  Obstructive complications of lichen sclerosus.

Authors:  Matthew S Christman; Jamesina T Chen; Nicholas M Holmes
Journal:  J Pediatr Urol       Date:  2009-01-30       Impact factor: 1.830

9.  Congenital phimosis in patients with and without lichen sclerosus: distinct expression patterns of tissue remodeling associated genes.

Authors:  Adrian Pilatz; Bora Altinkilic; Eileen Schormann; Lavinia Maegel; Nicole Izykowski; Jan Becker; Wolfgang Weidner; Hans Kreipe; Danny Jonigk
Journal:  J Urol       Date:  2012-11-20       Impact factor: 7.450

Review 10.  Diagnosis and treatment of lichen sclerosus: an update.

Authors:  Susanna K Fistarol; Peter H Itin
Journal:  Am J Clin Dermatol       Date:  2013-02       Impact factor: 7.403

View more
  5 in total

1.  Balanitis xerotica obliterans: An observational, descriptive and retrospective clinical study.

Authors:  Gyula László Fekete; Dominik Schwarzkopf-Kolb; Ilarie Brihan; Daniel Boda; László Fekete
Journal:  Exp Ther Med       Date:  2022-03-31       Impact factor: 2.447

2.  Could a careful clinical examination distinguish physiologic phimosis from balanitis xerotica obliterans in children?

Authors:  Filippo Ghidini; Calogero Virgone; Rebecca Pulvirenti; Emanuele Trovalusci; Piergiorgio Gamba
Journal:  Eur J Pediatr       Date:  2020-11-23       Impact factor: 3.183

3.  Twenty-year experience with macro-area school screening for andrological disease in paediatric age.

Authors:  Nicola Zampieri; Simone Patanè; Francesco Saverio Camoglio
Journal:  Andrologia       Date:  2021-08-11       Impact factor: 2.532

4.  Penile lichen sclerosus, circumcision and sequelae, what are the questions?

Authors:  Beth Morrel; Lisette A 't Hoen; Suzanne G M A Pasmans
Journal:  Transl Androl Urol       Date:  2022-07

5.  Comparison of lichen sclerosus in boys and girls: A systematic literature review of epidemiology, symptoms, genetic background, risk factors, treatment, and prognosis.

Authors:  Kajal S Kumar; Beth Morrel; Colette L M van Hees; Fred van der Toorn; Wendy van Dorp; Elodie J Mendels
Journal:  Pediatr Dermatol       Date:  2022-03-01       Impact factor: 1.997

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.